Zydus Lifesciences Limited has informed the Exchange regarding a press release dated February 28, 2026, titled "Zydus receives final approvals from USFDA for Ivermectin Tablets USP, 3 mg and Dapsone Tablets USP, 25 mg and 100 mg".
Press Release Feb 28 2026
Filed with NSE · · 2 pages · English
Summary by 6ix AI
Zydus Lifesciences Limited has issued a press release announcing final approvals from the USFDA for Ivermectin Tablets and Dapsone Tablets. The Ivermectin Tablets are indicated for treating parasitic worm infections, while Dapsone Tablets are used for leprosy and dermatitis herpetiformis. Both products will be manufactured in Ahmedabad and distributed by Viona Pharmaceuticals Inc.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Zydus Lifesciences Limited on 6ix
Earlier from Zydus Lifesciences
- Press Release Feb 27 2026
- Press Release Feb 25 2026
- Press Release Feb 19 2026
- Press Release Feb 18 2026
- Press Release Feb 17 2026
Later from Zydus Lifesciences
- Press Release Mar 12 2026
- Press Release Mar 13 2026
- Press Release Mar 14 2026
- Press Release Mar 16 2026
- Press Release Mar 17 2026
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences